Pan-Asia Catalysts/Events, Quiddity Advisors

Travis Lundy

HK Type 4 license through Ballingal Investment Advisors Ltd. ("BIA" or "BIAL")

BACKGROUND
I have 20+yrs experience in Asia doing alternative strategies (i.e. non-delta1 non long-only) in fixed income, equity derivatives, and activist/catalyst/event-driven and long-short equity strategies with most of that time spent managing money. 

4 years in fixed income macro, 8 years running internal hedge fund and 4yrs investment banking at Citi in Japan, 3 years running an Asia multi-strat portfolio at a hedge fund, 4+yrs as an independent special situations analyst.

Pan-Asia Catalysts/Events

Arteria Networks (4423) Tender Launches 5 July.

Arteria Networks (Buy) - Q1 22 Results Reaction: In-Line Quarter Includes 7% Revenue Growth

Arteria Networks (Buy) - Q2 22 Results Reaction: Core Business Growth Intact

Arteria Networks (Buy) - Q4 21 Results Reaction: Between a Rock and a Hard Place

Quiddity Advisors

Event-Driven

<ul>
<li>
<strong>Marubeni (8002 JP)</strong> and <strong>Secom (9735 JP)</strong><a href="https://www.smartkarma.com/entities/secom-co-ltd" target="_blank" data-smartkarma-citation="entities:11405:1" rel="noopener"></a> today announced a Tender Offer to take private Marubeni's subsidiary <a href="https://www.smartkarma.com/entities/arteria-networks-corp" target="_blank" data-smartkarma-citation="entities:27807:1" rel="noopener">ARTERIA Networks Corp (4423 JP)</a> at a 54% premium to the close. </li>
<li>Listed 4.5yrs ago, the company hasn't grown hugely. Revenue growth is slow. EBITDA growth is flat. The takeout is 3.6x book, 7x estimated EBITDA, and about mid-teens PER. Without synergies.</li>
<li>The price is OK, not great. The Board rejected the final price because it was too low and didn't include synergies, then accepted because the bidders wouldn't go further? Hmmm...</li>
</ul>



Marubeni (8002 JP) and Secom (9735 JP) today announced a Tender Offer to take private Marubeni's subsidiary ARTERIA Networks Corp (4423 JP) at a 54% premium to the close. 
Listed 4.5yrs ago, the company hasn't grown hugely. Revenue growth is slow. EBITDA growth is flat. The takeout is 3.6x book, 7x estimated EBITDA, and about mid-teens PER. Without synergies.
The price is OK, not great. The Board rejected the final price because it was too low and didn't include synergies, then accepted because the bidders wouldn't go further? Hmmm...


Marubeni & Secom To Launch Tender Offer for Arteria Networks (4423)